Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca secures approvals for cancer and asthma drugs in Japan
Lynparza has been approved as a maintenance treatment for patients in whom ovarian cancer had relapsed, and are sensitive to platinum chemotherapy. The approval for the treatment is
Lynparza has been approved as a maintenance treatment for patients in whom ovarian cancer had relapsed, and are sensitive to platinum chemotherapy. The approval for the treatment is
The investment will increase the good manufacturing practice (GMP) footprint at the campus by more than thrice. Slated to be operationally ready by the start of next year,
Argentum Pharmaceuticals brought the challenge to the patent, in a proceeding called inter partes review. Argentum disputed all claims of Janssen's U.S. Patent No. 8,822,438, which will expire on
Kymriah will be assessed under a priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with DLBCL who are ineligible for
Both OS and PFS were defined to be the dual primary endpoints of the pivotal late-stage trial dubbed KEYNOTE-189. The trial assessed the combination of Keytruda, Lilly’s pemetrexed
DIPG disease is mostly observed in young children with a median survival of nine months. Midatech Pharma said the approval of MTX110 trial is a big step towards development
Intellegens and Biorelate have AI tools, which can enhance e-Therapeutics’ existing computational network-driven drug discovery (NDD) technology. Intellegens is a spin-out from the University of Cambridge, which has developed an
The investment, which came in a Series A financing round, was co-led by new investors Google Ventures (GV) and Sequoia China alongside existing investor Oxford Sciences Innovation. Neptune
The partnership intends to develop a complete and final manufacturing process to enable CombiGene advance to commercial good manufacturing practices (GMP) production and subsequent clinical trials. CGT Catapult believes that
KWS BioTest specializes in in vitro and in vivo discovery testing services for immuno-oncology, inflammation and allergy, autoimmune disease and antimicrobials, antivirals, and vaccinology. The acquisition is expected to